Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007-2017
- PMID: 32128339
- PMCID: PMC7043807
- DOI: 10.1093/ofid/ofaa044
Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007-2017
Abstract
Among 25 291 and 4 921 830 people with and without hepatitis C, life expectancy at age 20 increased 1.8 years and 0.3 years from the interferon to interferon-free era, respectively. Increases were highest for racial and/or ethnic minority groups with hepatitis C.
Keywords: direct-acting antiviral agents; hepatitis C virus (HCV); mortality; survival; treatment.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
Similar articles
-
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.J Infect. 2014 Jan;68(1):1-20. doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4. J Infect. 2014. PMID: 24012819 Review.
-
Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs.J Sex Med. 2019 Mar;16(3):402-409. doi: 10.1016/j.jsxm.2019.01.309. J Sex Med. 2019. PMID: 30846113
-
Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.Clin Infect Dis. 2016 Jul 15;63 Suppl 1(Suppl 1):S3-S11. doi: 10.1093/cid/ciw219. Clin Infect Dis. 2016. PMID: 27363438 Free PMC article. Review.
-
Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.J Viral Hepat. 2017 Aug;24(8):624-630. doi: 10.1111/jvh.12684. Epub 2017 Feb 20. J Viral Hepat. 2017. PMID: 28130810
-
Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22. Clin Gastroenterol Hepatol. 2013. PMID: 23707354
Cited by
-
Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.J Thromb Haemost. 2021 Jan;19 Suppl 1(Suppl 1):32-41. doi: 10.1111/jth.15187. J Thromb Haemost. 2021. PMID: 33331041 Free PMC article.
-
Mortality Evaluation and Life Expectancy Prediction of Patients with Hepatocellular Carcinoma with Data Mining.Healthcare (Basel). 2023 Mar 22;11(6):925. doi: 10.3390/healthcare11060925. Healthcare (Basel). 2023. PMID: 36981582 Free PMC article.
-
Adverse outcomes after surgeries in patients with liver cirrhosis among Korean population: A population-based study.PLoS One. 2021 Jun 14;16(6):e0253165. doi: 10.1371/journal.pone.0253165. eCollection 2021. PLoS One. 2021. PMID: 34125860 Free PMC article.
-
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database.J Thromb Haemost. 2021 Jan;19 Suppl 1(Suppl 1):21-31. doi: 10.1111/jth.15186. J Thromb Haemost. 2021. PMID: 33331042 Free PMC article.
-
Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals.Cancer Epidemiol Biomarkers Prev. 2021 Dec;30(12):2188-2196. doi: 10.1158/1055-9965.EPI-21-0742. Epub 2021 Sep 28. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 34583968 Free PMC article.
References
-
- Powderly WG, Naggie S, Kim AY, et al. . IDSA/AASLD response to cochrane review on direct-acting antivirals for hepatitis C. Clin Infect Dis 2017; 65:1773–5. - PubMed
-
- Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology 2018; 68:827–38. - PubMed